In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research
As we hit the Q2/Q3 mark in this very hot summer, the hires chatter is not exactly heating up, but we did see a steady beat of news in July, including a lot of new CEOs.
March wasn’t the busiest month for big pharma shakeups, especially compared to the start of the year, but there was plenty of hustle and bustle at smaller pharma and biotech firms.
